Astellas Pharma’s R&D program developed treatment for prostrate cancer & urinary frequency diseases
Register to read the full analysis —or— Upgrade to access more features
#Astellas Pharma
#Xtandi
#Breakthrough Drug
#Myrbetriq
Actual Direct Impact
Share this Analysis
Keen to rectify an issue with this analysis?
Report issue
There is no comment yet.